The consequences if presynaptic action potentials In an axon release insufficient acetylcholine to depolarize a skeletal muscle fiber to threshold
Explanation:
When an action potential reaches a neuromuscular junction, it causes acetylcholine to be released into this synapse. The acetylcholine binds to the nicotinic receptors concentrated on the motor end plate, a specialized area of the muscle fibre's post-synaptic membrane.
Acetylcholine is the neurotransmitter used at the neuromuscular junction—in other words, it is the chemical that motor neurons of the nervous system release in order to activate muscles. ... In the brain, acetylcholine functions as a neurotransmitter and as a neuromodulator.
The process for the expected outcomes include:
The outcomes are derived from nursing diagnoses.
The outcomes are measurable goals.
The outcomes include a time estimate for the achievement of short- and long-term outcomes.
<h3>What does "care plan" mean?</h3>
The services and assistance being provided to a person are simply described in a plan of care, which is a presentation of information. Care planning and review should be done in conjunction with the individual on whose care they are focused.
It should be noted that in this case, the nurse is revising a client’s care plan. Therefore, it's important to know the process for the expected outcomes include the fact that the outcomes are derived from nursing diagnoses and other parts illustrated above.
Learn more about care plan on:
brainly.com/question/28421958
#SPJ1
C. The meniscus is a piece of cartilage in the knee that provides a cushion between your femur (thighbone) and tibia (shinbone).
DKA occurs because pumps do not use long-acting insulin. Pumps are usually filled with rapid-acting insulin (such as lispro, aspart or glulisine) that starts working I think thats right but im not sure
The correct answer is Due to study design restrictions, an unfavorable total population size, the possibility of publication bias, and heterogeneity between studies, the quality of the evidence for the outcome of invasive fungal infection, superficial fungal infection, fungal colonization, and adverse events necessitating therapy cessation was low.
Ketoconazole and a placebo were evaluated in three trials. In one trial, anidulafungin was put up against a placebo. In one trial, caspofungin was compared to a placebo. Micafungin was put in two trials with a placebo. Amphotericin B and a placebo were evaluated in one trial. One experiment evaluated the impact of clotrimazole, ketoconazole, nystatin, and no treatment, while two trials compared the effect of nystatin to placebo. Four new research are awaiting classification, and there are two new ongoing trials. Participants in the RCTs were of both sexes, and they ranged widely in age, critical illness severity, and clinical features. Eleven trials reported pharmaceutical company financing, one trial claimed support from a government body. For the major review domains, the majority of the studies exhibited a generally unknown risk of bias.
Learn more about Amphotericin B here:-
brainly.com/question/4652591
#SPJ4
